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Abstract The adhesion of human polymorphonuclear granulo-
cytes (PMN) with confluent human endothelial cells (line
EAhy926) and with solid substrate coated by collagen and
fibronectin (Fn) was studied by phase contrast microscopy and by
the measurement of myeloperoxidase activity. The ecto-ATPase
inhibitors suramin and Reactive Blue 2 (RB2) more than doubled
the adhesion of PMN to endothelial cells. The cells hydrolyzed
added ATP and this reaction was inhibited by suramin and RB2.
The degree of ATP hydrolysis during PMN adherence depended
on solid substrata and decreased in the order: non-stimulated
endothelial cells, TNF-stimulated endothelial cells, collagen-
coated surface, Fn-coated surface. In the same order adherence
increased. The endogenous level of extracellular ATP in the
PMN-endothelial coculture was around 25 nM.
We conclude that PMN-endothelial adhesion is counteracted by
an ecto-ATPase or by ATP receptors with ATPase activity.
Such interactions may play a role in PMN rolling and diapedesis
as well as in the pathophysiology of PMN activation by an
anergic endothelium.
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1. Introduction
Leukocyte recruitment to the tissue sites of in£ammation
requires a complex interaction between circulating polymor-
phonuclear leukocytes (PMN) and the endothelium including
the subendothelial matrix [1]. What is considered as a phys-
iological defence mechanism against invading microorganisms
can under severe ischemia-reperfusion or shock conditions
turn into a self-destructive mechanism (of an organ) and
thus may be lethal to an organism [2^4]. Therefore the mech-
anisms of PMN adhesion to the endothelium and the subse-
quent steps in diapedesis have been extensively studied in
order to ¢nd pharmacological targets.
Both leukocytes and the endothelium play an active part in
these processes which are governed by adhesion molecules and
their receptors [5^8]. Integrins, selectins and proteins of the
immunoglobulin gene superfamily mediate the various stages
of adhesion which turns out to be an active and energy-utiliz-
ing process. Since ATP is required to synthesize, express and
degrade components of the adhesion mechanism it explains
why cooling of tissues prevents destructive processes in trau-
matic or ischemia-reperfusion events [9^12]. On the other
hand under physiological conditions energy is also required
to prevent leukocyte adhesion to the endothelium through
synthesis of nitric oxide or prostacyclin [13,14], which by in-
tracellular cGMP- or cAMP-dependent phosphorylations ac-
tively counteract a sticking of PMN to the endothelium. It
had even been suggested that ATP directly controls adhesion
by ATP receptors or ecto-ATPases [15].
In this paper we made use of ecto-ATPase inhibitors and
ATP receptor antagonists to look for a correlation between
extracellular ATP hydrolysis and neutrophil adhesion during
neutrophil interaction with di¡erent surfaces. We found
microscopic and biochemical evidence that indeed the ecto-
ATPase and/or ATP receptor antagonists suramin and Reac-
tive Blue 2 (RB2) increase adhesion of human PMN to con-
£uent endothelial EAhy926 cells. The increase of adhesion to
suramin treatment correlated with a decrease of extracellular
ATP hydrolysis to this treatment. The fact that suramin and
RB2 acted di¡erently on the adhesion of PMN to ¢bronectin
allowed to conclude on a rather speci¢c action of ATP.
2. Materials and methods
The endothelial permanent cell line EAhy926 was a kind gift of Dr.
Cora-Jean S. Edgell (University of North Carolina, USA). Dulbecco’s
modi¢ed Eagle’s medium (DMEM), HAT-supplement, L-glutamine,
penicillin, streptomycin were purchased from Gibco (Eggenstein, Ger-
many), fetal calf serum (FCS) and collagen type I from Boehringer
Mannheim (Mannheim, Germany), human plasma ¢bronectin (Fn)
from Calbiochem (San Diego, CA, USA). Tumor necrosis factor
was from Falcon (Franklin Lakes, NJ, USA). Ficoll-Paque was pur-
chased from Pharmacia (Uppsala, Sweden). HEPES, ortho-phenyl-
enediamine were purchased from Fluka (Deisenhofen, Germany).
ATP, ADP, AMP, adenosine, erythro-9-(2-hydroxy-3-nonyl)adenine
(EHNA), adenosine deaminase, ouabain, trypsin-EDTA were pur-
chased from Sigma (Deisenhofen, Germany).
2.1. Preparation of biological surfaces for leukocyte adhesion
Tissue culture plastic 24-well plates were coated with collagen
(75 Wg/ml, for 24 h) or Fn (3 Wg/ml, for 3^5 h). Collagen-coated
culture plates were washed with DMEM with 0.5% FCS and used
for adherence and for endothelial cell culture. Before use dishes
were thoroughly washed with phosphate-bu¡ered saline (PBS).
2.2. Cell culture conditions and treatment
Endothelial cell permanent culture EAhy926, passages 179^185,
maintained in HAT-supplemented (100 WM hypoxanthin, 0.4 WM ami-
nopterin, 16 WM thymidin) Dulbecco’s modi¢ed Eagle’s medium
(DMEM) with 4.5 g/l glucose, 4 mM L-glutamine, 10 U/ml penicillin,
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10 Wg/ml streptomycin, and 10% FCS, as recommended by Edgell et
al. [16]. Cultures were passaged weekly using trypsin-EDTA solution
(500 BAEE units trypsin and 180 Wg EDTA/ml in PBS), and seeded
on 24-well plates, or 75 cm2 culture £acons, coated by collagen. One
or 2 days before the experiments, the medium was exchanged for
DMEM with 0.5% FCS. When indicated, the cells were activated by
TNF-K, added to this medium for 6 h at a concentration 8 ng/ml.
2.3. PMN isolation procedure
PMNs were isolated from freshly drawn donor blood on a bilayer
gradient of Ficoll-Paque (1.077 and 1.125 densities). Granulocytes
were washed twice in PBS and resuspended in Hanks’ balanced salts
solution (HBSS) with 10 mM HEPES, pH 7.4.
2.4. Phase contrast microscopy of cell cultures
PMNs were added to control or activated (TNF-K, 8 ng/ml, 6 h)
EAhy926 cells grown to monolayer on collagen-coated cover slips, for
20 min at 37‡C. After washing with PBS, the samples were examined
with an Opton-III Microscope (Zeiss, Germany).
2.5. PMN adhesion assay
Myeloperoxidase activity was used as a marker enzyme to measure
polymorphonuclear leukocyte (PMN) adherence to endothelial cells
and to collagen- or ¢bronectin-coated surfaces. PMNs were added
to 24-well culture plates containing an endothelial cell (EAhy926)
monolayer, or coated by ¢bronectin or collagen, (5U105 PMNs per
well, in 500 Wl of HBSS medium with 10 mM HEPES, pH 7.4). After
30 min incubation in a CO2 incubator at 37‡C to allow leukocyte
adherence, wells were washed 2 times with 500 Wl PBS solution, for
removal of non-adherent PMN. The amount of adherent PMN was
measured by the addition of detergent and a peroxidase substrate, as
described [17,18]. 300 Wl of a solution of 5.5 mM ortho-phenylenedi-
amine and 4 mM H2O2 in bu¡er (67 mM Na2HPO4, 35 mM citric
acid, 0.1% triton X-100, pH 5), were added to each well, and after
4 min, the reaction was stopped by the addition of the equal volume
of 1 M H2SO4. Standard dilutions of PMN with or without tested
compounds were used for calibration.
2.6. Ecto-ATPase activity assay
Hydrolysis of exogenously added ATP by the endothelial cell cul-
ture, by the PMN-endothelial cell coculture, and by PMNs on colla-
gen or ¢bronectin, was determined by HPLC analysis of the super-
natants collected at timed intervals and assayed for nucleotide
concentrations. Cell incubations were performed in HBSS/HEPES
medium. Suramin (100 WM), when indicated, was added to the me-
dium before the PMN. PMNs were added to endothelial monolayers,
or to collagen- or Fn-coated surfaces in 24-well plates, 5U105 cells/
well. ATP at concentrations of 100^1000 WM was added after PMN,
and plates were incubated at 37‡C in a CO2 incubator. At regular
intervals, 250 Wl of supernatant was taken and mixed with 50 Wl of a
solution consisting of 50 mM EDTA and 0.9% NaCl to stop the
reaction. The amount of nucleotide in the dish without cells was
also measured as a control. Adenine nucleotides and adenosine in
samples were determined by reversed phase HPLC on C18 (25 cm
U4.6 mm) 5 Wm column. After 7 min elution with bu¡er A (2 ml
85% H3PO4 in 1000 ml H2O, titrated to pH 5 with NH4OH), fraction
B (H2O/acetonitrile, 1:1) was increased to 50% during 10 min. Nu-
cleotides were detected at 254 nm.
2.7. Release of ATP, NO and prostacyclin
PMNs were added to 24-well culture plates, with endothelial cell
(EAhy926) monolayers, or coated by ¢bronectin or collagen, 5U105
PMNs per well, in 500 Wl of HBSS medium with 10 mM HEPES, pH
7.4. After 30 min incubation in a CO2 incubator at 37‡C for leukocyte
adherence, plates were centrifuged at 2000Ug for 3 min. 200 Wl ali-
quots of supernatant were mixed thoroughly with an equal volume of
icecold 4 mM EDTA and 20 Wl of 0.1 M KOH adjusted pH 7.7. The
samples were centrifuged at 2000Ug for 3 min and the supernatant
was stored at 370‡C until analysis. The concentration of ATP in the
samples was determined by an ATP bioluminescent assay kit (Sigma)
according to the instructions of the manufacturer. Suramin interfered
in this assay. NO was measured by the Griess test [19] and prostacy-
clin formation with a 6-keto-prostaglandin F1K ELISA test [20].
3. Statistical analysis
Results are given as means þ S.E.
4. Results
4.1. ATPase inhibitors and PMN adhesion
Table 1 shows the e¡ect on adhesion of PMN when the
coculture was supplemented with the mitochondrial uncoupler
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Table 1
E¡ects of di¡erent ATPase inhibitors and ATP on adhesion of PMNs to endothelial cells and to collagen
Adhesion, %
PMN adhesion to EAhy926 cells PMN adhesion to collagen
Control 6.8 þ 1.2 20 þ 2.0
Oligomycin, 10 WM 7.2 þ 1.0 22 þ 2.3
Ortho-vanadate, 200 WM 7.0 þ 1.1 20 þ 1.8
Ouabain, 200 WM 7.0 þ 1.0 26 þ 3.0
Suramin, 100 WM 15 þ 3 35 þ 5
Reactive Blue 2, 100 WM 25 þ 2 50 þ 5
ATP, 10 WM 9.1 þ 1.5 23 þ 2
A suspension of PMNs (106/ml) was added to a non-stimulated (control) endothelial monolayer, or to collagen-coated surface. Indicated com-
pounds were added to HBSS incubation medium before PMNs. After 30 min incubation at 37‡C, non-adherent leukocytes were washed out by
rinsing.
Fig. 1. Dependence of PMN adherence to endothelial EAhy926
cells, and to collagen- and ¢bronectin-coated surfaces on Suramin
and Reactive Blue 2. Suspension of PMNs 106/ml incubated on var-
ious biological surfaces with or without Suramin and RB2 in incu-
bation medium. After 30 min at 37‡C, non-adherent leukocytes
were washed out by rinsing.
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oligomycin, the inhibitor of ion pumping ATPases, Na-ortho-
vanadate and the Na/K-ATPase blocker ouabain. No signi¢-
cant e¡ects were seen. But suramin and RB2, which have been
described as inhibitors of ecto-ATPases and/or P2-purinocep-
tor antagonists caused a strong adhesion of PMN to endothe-
lial cells and to collagen (Figs. 1 and 2). Both agents did not
a¡ect the adhesion to ¢bronectin (Figs. 1 and 2). Exogenously
added ATP increased adhesion of PMN to endothelial mono-
layers and to collagen (Table 1). Phase contrast microscopy of
PMN-endothelial cocultures in the presence of suramin
showed £attened and spreaded PMN adhered to the intercel-
lular space (Fig. 2).
4.2. Extracellular ATP hydrolysis during PMN adhesion
When ATP hydrolysis was measured in cocultures of PMN
and EAhy926 cells di¡erences were found which correlated
inversely with the adhesion process. An HPLC pro¢le of the
ATP hydrolysis products with and without suramin is shown
in Fig. 3. Because of the presence of ADP hydrolysis and
AMP-5P-nucleosidase activity, the ratio of ADP+AMP+ade-
nosine to ATP has been used as a measure of ATPase activity.
Controls had a high activity of about 20% which decreased
dramatically to 5^6% in the presence of suramin and RB2 (for
RB2 data not shown).
One possible explanation for these results could have been
the production of adenosine from ATP and the subsequent
activation of adenosine receptors. After a 30 min incubation
of 100 WM ATP with a PMN-human umbilical vine endothe-
lial cell coculture about 4^5 WM adenosine could be measured,
the level of extracellular adenosine was very low in PMN-
EAhy926 cell coincubations, and Fig. 4 shows that adenosine
could only partly reverse the suramin and RB2 e¡ect on ad-
hesion. The presence of adenosine deaminase (up to 1 U/ml)
was without e¡ect but EHNA, an inhibitor of adenosine de-
aminase (Fig. 3A), raised the adenosine concentrations to a
detectable level and also decreased the RB2 induced adhesion
process (Fig. 4).
If extracellular ATP directly would be responsible for a
decreased adhesion in the coculture system distinct levels of
ATP should be detectable under steady state conditions. We
found that controls built up an ATP level of 13 nM which
further increased to 25 nM in the presence of RB2. On a
collagen surface a concentration of 10 nM and on a ¢bronec-
tin surface a concentration of 6 nM were found, obviously
originating from a secretion by PMN.
An alternative explanation of the data would be possible by
an increase of NO or prostacyclin production by the EAhy926
cells. However, no stimulation of NO synthesis and no en-
hancement of 6-keto-PGF1K formation could be detected.
5. Discussion
Under normal conditions of blood £ow and average oxygen
tension the vascular system uses several mechanisms to avoid
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Fig. 2. a: Microscopy of PMN-endothelial cell coculture (arrows indicate PMNs) in the absence (left) and in the presence of 100 WM suramin.
b and c: Microscopy of PMNs on collagen- and on ¢bronectin-coated surfaces, in the absence (left) and in the presence of 100 WM suramin.
Bar, 10 Wm.
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sticking of blood cells to the vessel wall. The endothelium
plays an active part in this process by secreting prostacyclin,
nitric oxide (NO) or the still uncharacterized endothelium-de-
rived hypopolarizing factor (EDHF) in response to shear
stress or humoral factors. It also has been suggested that
ATP secretion [21] from endothelial cells acts in the same
direction through ATP receptors which again cause the release
of NO and prostacyclin [13,22,23] and thus prevent PMN
adhesion. However, no increases of NO production or pros-
tacyclin synthesis in EAhy926 cells were detected in the pres-
ence of ATP.
Our present results allow an additional explanation by as-
suming the involvement of ecto-ATPases. Based on previous
reports on the inhibition of such ATPases by suramin and
RB2 [24^26] we could show that blocking of ecto-ATPases
leads to an increased adherence of PMN to a con£uent endo-
thelial cell culture. From this we conclude that an active
ATPase on endothelial cells keeps PMN in a state of loose
attachment whereas a decrease of ATPase activity in the pres-
ence of suramin or RB2 causes a transition to a tightly at-
tached state. This is further supported by measurements of
ATP breakdown, which was inversely correlated with the ad-
hesion process. Suramin and RB2 block this ATPase activity.
Collagen-coated surfaces but not those coated with ¢bronec-
tin behaved similarly to endothelial monolayers suggesting
that collagen receptors on PMN may also participate in the
anti-adhesive process.
It is known that vascular endothelial cells [27] and PMNs
[25] are equipped with ecto-ATPases and 5P-nucleotidases, the
key enzymes for the metabolism of adenine nucleotides. The
detailed mechanisms by which ATPases counteract the adhe-
sive process are not known. The hypothesis that the cell ad-
hesion molecule CAM 105 is itself an ecto-ATPase [28] found
no support by an investigation carried out by Stout and Kir-
ley [29]. It is intriguing, however, to assume that ATP ex-
truded from the cells exerts a signalling function between
PMN and the endothelium and that ceasing of the outward
transport leads to tight adherence of PMN in the intercellular
space as observed in the present experiments.
Whether the transducing system is mainly a receptor or an
ATPase that uses the chemical energy for active anti-adhesive
processes is still not clear. It even becomes more complex
when the further steps in ATP degradation are also consid-
ered. Except an ecto-ATPase there exists an ecto-5-nucleo-
tidase generating adenosine which a¡ects cell functions
through purinoceptors. These receptors are subdivided into
two classes: P1 with an agonist potency order of adenosine
sAMPsADPsATP and P2 with a reverse ranking [30]. P1
receptors are divided into A1 and A2 subtypes [31], and ad-
enosine, possessing high a⁄nity to adenosine A2 receptors is
known to inhibit neutrophil adhesive interactions [32]. In the
light of this interaction between ATP and the purinergic re-
ceptors the hypothesis of Cunningham et al. [33] that ecto-
ATPase may serve as a switch controlling extracellular ATP
concentration and ligand accessibility to P1- and P2-purino-
ceptors, also seems to be attractive. As the main physiological
role for endothelial ecto-nucleotidases their antithrombotic
activity has been postulated [34] by their ability to hydrolyse
the pro-aggregatory ADP [35]. That the formation of adeno-
sine as the end product of ATP hydrolysis plays an important
role in decreasing neutrophil adhesion, is supported by many
investigations [32,36,37]. Also according to our data, adeno-
sine could participate in preventing adhesion, but adenosine
and the adenosine deaminase inhibitor EHNA only partly
reversed the e¡ect of RB2 on neutrophil adhesion to endothe-
lial cells and to collagen, though EHNA increased the adeno-
sine concentration in incubations up to micromolar levels.
Adenosine can inhibit adhesion of neutrophils in concentra-
tions as low as 10 nM [38]. Since this is well below the HPLC
detection level, we cannot exclude that low amounts of ad-
enosine were formed and supported the low basal adhesion in
our PMN-EAhy926 cocultures.
Irrespective of the chain of events starting from ATP secre-
tion it seems established that extracellular ATP plays an active
role in the anti-adhesive mechanism between the endothelium
and PMN, and probably also other blood cells. To support
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Fig. 4. E¡ect of adenosine and EHNA on suramin- and RB2-stimu-
lated PMN adhesion to collagen and endothelium. Suramin, 100
WM, RB2, 100 WM, adenosine, 1 mM, or EHNA, 1 WM added to
HBSS incubation medium before the addition of the suspension of
PMNs 106/ml. After 30 min at 37‡C, non-adherent leukocytes were
washed out by rinsing.
Fig. 3. A: Extracellular ATP hydrolysis during PMN adhesion to endothelial cell EAhy926 monolayer. HPLC pro¢les of the products of ATP
hydrolysis: a: the standard mixture of ATP, ADP, AMP and adenosine (Ado); b and c: the supernatants from PMN-endothelial cell coincuba-
tions 30 min at 37‡C with 200 WM ATP, with (c) or without (b) 2 WM EHNA. B: Extracellular ATP hydrolysis during PMN adhesion to dif-
ferent surfaces, e¡ect of suramin. Extracellular nucleotides in PMN incubations on di¡erent surfaces with 100 WM exogenously added ATP de-
termined by HPLC. Data are presented as the ratio of products of ATP hydrolysis (ADP and AMP were determined, Ado was below
detection level in these incubations) to ATP concentration in the supernatants after 15 and 30 min at 37‡C, with or without suramin in HBSS
incubation medium.
6
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this hypothesis it was important to detect extracellular ATP in
our system. Indeed the medium contained 25 nM ATP in the
coculture and 10 nM after a 30 min incubation of PMN with
collagen surfaces. These levels amount to those found after
the same time interval in a HL60 promyelocyte cell culture
[39].
Taken together we suggest from our data that extracellular
ATP can e¡ectively counteract adhesion by a process that is
sensitive to suramin and RB2, which have been reported as
inhibitors of ecto-ATPase activity. Further studies must clar-
ify the complex interplay of the presumed ecto-ATPase with
ATP and adenosine receptors.
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